Clinical Trials Browser

Completed × NIH × navitoclax × Clear all

NCT02143401 2024-11-22

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Phase 1 Completed

Gastrointestinal

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms

NCT02520778 2024-08-21

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Completed

Advanced Lung Non-Squamous Non-Small Cell Carcinoma